Immunometabolic biomarkers of XXXX in Beh  et's disease: Relationship with epidemiological profile, disease activity and therapeutic regimes.

@entity1 @entity32 @entity650 @entity3335 @entity5 @entity11603 @entity2842 @entity2403 @entity2159
UNASSIGNED: @entity2403 ( @entity2403 ) is a systemic @entity32 with a still unclear pathogenesis. Although several inflammatory molecules have been studied current biomarkers are largely insensitive in @entity2403 and unable to predict disease progression and response to treatment. Our primary aim was to explore serum levels of soluble @entity11603 (sCD40L), soluble intracellular adhesion molecule (sICAM-1), @entity2842 ( @entity2842 ), @entity3335 ( @entity3335 ), leptin, resistin, @entity2159 ( @entity2159 ), soluble type 1 @entity5 necrosis factor receptor (sTNFR) and @entity650 ( @entity650 ) and SAA serum concentration in a cohort of 27 @entity2403 @entity1 . The secondary aim was to evaluate potential correlations between the putative circulating biomarkers, demographic profile of @entity1 , the status of disease activity, the specific organ involvement at the time of sample collection and different therapeutic regimes. Serum concentrations of sTNFR (p=0.008), leptin (p=0.0011), sCD40L (<0.0001), and @entity650 (p=0.0154), were significantly higher in @entity2403 @entity1 than in HC, while no difference was found in @entity2842 , @entity3335 and resistin serum levels. Moreover, we observed significantly higher sTNFR serum concentrations in @entity2403 @entity1 presenting inactive disease than HC (p=0.0108). A correlation between sTNFR and age was also found, with higher levels in @entity1 over 40 years than HC (p=0.0329). Although further research is warranted to elucidate the role of circulating biomarkers, some of that may contribute to the understanding of the physiopathology processes underlying @entity2403 activity and damage as well as to provide useful tools for prognostic purposes and a personalized treatment approach. This article is protected by copyright. All rights reserved.
